8-K: Century Therapeutics Q1 2026 Results: Pipeline Advances, Cash Runway Extended

Century Therapeutics reported Q1 2026 financial results, highlighting progress in its type 1 diabetes and cancer cell therapies, with a cash runway extending into Q1 2029.

Summary

• Century Therapeutics reported its financial results for the first quarter ended March 31, 2026.
• The company made progress on its lead type 1 diabetes therapy, CNTY-813, with IND submission expected in Q4 2026 and initial clinical data in 2H 2027.
• CNTY-308, a CAR-iT cell therapy for B-cell-mediated diseases, is on track to advance into clinical trials in 2026.
• The company ended the quarter with $217.0 million in cash, cash equivalents, and marketable securities.
• This cash position is expected to support operations into the first quarter of 2029.
• Research and Development expenses decreased to $17.1 million from $26.6 million in Q1 2025.
• General and Administrative expenses also decreased to $6.6 million from $8.4 million in Q1 2025.
• The company reported a net loss of $21.6 million for the quarter.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to significant pipeline progress and extended cash runway, despite a net loss and zero collaboration revenue this quarter.

Positives

• Cash, cash equivalents, and marketable securities increased to $217.0 million as of March 31, 2026, from $117.1 million as of December 31, 2025.
• The company's cash runway is estimated to extend into the first quarter of 2029.
• CNTY-813, the type 1 diabetes therapy, is on track for IND submission in Q4 2026, with initial clinical data expected in 2H 2027.
• CNTY-308 is on track to advance into the clinic in 2026.
• Research and Development expenses decreased to $17.1 million from $26.6 million year-over-year.
• General and Administrative expenses decreased to $6.6 million from $8.4 million year-over-year.
• Completed an oversubscribed $135 million private placement financing in January 2026.

Negatives

• Reported a net loss of $21.6 million for the quarter ended March 31, 2026.
• Collaboration revenue was $0 for the quarter ended March 31, 2026, compared to $109.2 million for the same period in 2025.
• Net income (loss) per common share was $(0.11) for the quarter ended March 31, 2026, compared to $0.89 for the same period in 2025.

Risks

• The company's ability to successfully advance its current and future product candidates through development activities, preclinical studies, and clinical trials.
• Uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results.
• The timing, scope and likelihood of regulatory filings and approvals.
• The impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on business and operations, supply chain and labor force.
• Reliance on the maintenance of certain key collaborative relationships for manufacturing and development.
• The performance of third parties in connection with development, including clinical trials and manufacturing.
• The ability to successfully commercialize product candidates and develop sales and marketing capabilities.
• The ability to recruit and maintain key members of management and enforce adequate intellectual property protection.

Future Outlook

The company expects to submit an IND for CNTY-813 in Q4 2026 and anticipates initial clinical data in the second half of 2027. CNTY-308 is on track to initiate clinical testing in 2026. The current cash position is expected to support operations into Q1 2029.

Management Comments

• "We are executing our pipeline with discipline to deliver an iPSC-derived islet replacement therapy to patients."
• "The progress of CNTY-813 highlights what Century can achieve pairing our Allo-Evasion engineering with a scalable iPSC platform."
• "In a relatively short time since initiating this program, we have advanced CNTY-813 into IND-enabling studies on a timeline we believe is highly competitive with leading efforts in the field."
• "With an IND submission expected in the fourth quarter of 2026 and initial clinical data anticipated in the second half of 2027, our focus is clear: to deliver a differentiated, patient-centric, potentially curative approach for people with type 1 diabetes while continuing to expand our autoimmune disease portfolio with CNTY-308."

Industry Context

StockSavvy.ai notes that Century Therapeutics is operating in the highly competitive and rapidly evolving fields of cell therapy for autoimmune diseases and cancer. The company's focus on iPSC-derived therapies and immune evasion technology positions it among a cohort of biotech firms aiming for 'off-the-shelf' solutions, which could significantly impact patient access and treatment paradigms if successful.

Comparison to Industry Standards

• The timeline for IND submission for CNTY-813 (Q4 2026) and initial clinical data (2H 2027) is presented as competitive with leading efforts in the type 1 diabetes cell therapy space.
• Preclinical data for CNTY-308 showed functional comparability to primary CAR-T cells, a standard benchmark in the CAR-T therapy field.

Stakeholder Impact

• Shareholders: Extended cash runway provides more time for pipeline development and potential value creation, but the net loss and lack of collaboration revenue may be a concern.
• Patients: Progress in CNTY-813 offers potential for a functional-cure for type 1 diabetes, and CNTY-308 could provide new treatment options for B-cell-mediated diseases.
• Employees: Continued pipeline advancement and financial stability support ongoing operations and research efforts.

Next Steps

• Submit IND for CNTY-813 in Q4 2026.
• Present CNTY-813 preclinical data at ADA Scientific Sessions on June 8, 2026.
• Initiate clinical testing for CNTY-308 in 2026.
• Anticipate initial clinical data for CNTY-813 in 2H 2027.

Key Dates

Recommendation

The company shows promising pipeline progress and a strong cash position, extending its runway. However, the significant net loss and absence of collaboration revenue this quarter, coupled with the long development timelines for its therapies, warrant a cautious 'hold' recommendation until further clinical data emerges.

Keywords

Century Therapeutics, CNTY-813, CNTY-308, iPSC, cell therapy, type 1 diabetes, autoimmune disease, cancer